Author:
Aboras Sara I.,Megahed Ahmed A.,El-Yazbi Fawzy,Maher Hadir M.
Abstract
AbstractSARS-CoV-2 virus triggered a worldwide crisis, with world nations putting up massive efforts to halt its spread. Molnupiravir (MLN) was the first oral, direct-acting antiviral drug approved for nasopharyngeal SARS-CoV-2 infection with favorable safety and tolerability profile. This study aims at determination of MLN and N4-hydroxycytidine (NHC), its main degradation product and its main metabolite, using sensitive, simple, and green HPLC–DAD method. Moreover, under different stress conditions using NaOH, HCl, neutral, H2O2, dry heat and sun light, the method was applied for MLN assay along with kinetics degradation investigation. The linearity range for MLN and NHC were both 0.1–100 µg/mL with LOD and LOQ of 0.013 & 0.043 and 0.003 & 0.011 µg/mL, for MLN and NHC, respectively. MLN was found to be extremely vulnerable to alkali hydrolysis compared with acid and dry heat degradation. In contrast, MLN was stable under conditions of oxidative, neutral, and sunlight-induced deterioration. Acid and alkali-induced degradation followed pseudo first-order kinetics model. In addition, LC–MS-UV was used to suggest the mechanism of the stress-induced degradation route and to characterize the eluted degradation products. Toxicities of both MLN and its degradation products were evaluated using ProTox-II and they were found to be negligibly harmful. The proposed HPLC–DAD was effectively used for the analysis of MLN in commercial pharmaceutical formulations. The proposed method for MLN determination after greenness and whiteness appraisal was found to be superior compared to the reported methods for MLN analysis.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Machhi, J. et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharmacol. 15(3), 359–386. https://doi.org/10.1007/s11481-020-09944-5 (2020).
2. Painter, G. R., Natchus, M. G., Cohen, O., Holman, W. & Painter, W. P. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 50, 17–22 (2021).
3. Painter, W. P. et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 65(5), e02428-e2520. https://doi.org/10.1128/AAC.02428-20 (2021).
4. Teli, D. et al. Molnupiravir: a versatile prodrug against SARS-CoV-2 Variants. Metabolites. 13(2), 309. https://doi.org/10.3390/metabo13020309 (2023).
5. LiverTox: Clinical and Research Information on Drug Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Molnupiravir. [Updated 2022 Jan 31]. Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/ (Accessed September 2023).